Valeant sets sights on Zoetis; Report: VC cash follows male boards and CEOs;

@FierceBiotech: Harvard team makes 'sweating' vehicles for liquid drug delivery. FierceDrugDelivery story | Follow @FierceBiotech

@JohnCFierce: Big story yesterday: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus Hubs win. Report | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> The boards of successful biotech companies remain overwhelming male-dominated, according to a new report from Liftstream examining the gender constitution of drug developers that get venture financing. More

> Eli Lilly ($LLY) and Adocia are heralding success in a Phase Ib trial of a fast-acting insulin. News

> Valeant ($VRX) is reportedly bidding for Zoetis ($ZTS), the animal health-focused company that spun off from Pfizer ($PFE) in 2013. Story

Medical Device News

@FierceMedDev: Cinven snatches up Synlab for $1.96B to beef up in diagnostics. FierceDiagnostics news | Follow @FierceMedDev

@VarunSaxena2: Valeant makes offer for Zoetis, sources tell WSJ. FiercePharma story | Follow @VarunSaxena2

@EmilyWFierce: $ILMN just signed a 20-year lease for a new 155,000 square foot scientific research building in England. Release | Follow @EmilyWFierce

> BlackBerry unveils plans for bacteria-free smartphone device. More

> European researchers develop thought-controlled robot. Article

Pharma News

@FiercePharma: Egg prices soar, menu items dropped in wake of historic avian flu. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: France's TxCell closes its plant at ANSM urging to avoid contamination. FiercePharmaManufacturing article | Follow @EricPFierce

> Nurse pleads guilty to taking Insys kickbacks as Subsys marketing probe continues. Report

> Sanofi's Brandicourt faces skeptical unions, anxious shareholders. Story

> Valeant makes offer for Zoetis, sources tell WSJ. Article

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.